Cell cycle regulators cyclin D1 and CDK4/6 have estrogen receptor-dependent divergent functions in breast cancer migration and stem cell-like activity

References

• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74 - 108; http://dx.doi.org/10.3322/canjclin.55.2.74; PMID: 15761078
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687 - 717; http://dx.doi.org/10.1016/S0140-6736(05)66544-0; PMID: 15894097
   PubMed Web of Science ®Google Scholar
• Jensen EV, Jordan VC. The estrogen receptor: a model for molecular medicine. Clin Cancer Res 2003; 9:1980 - 9; PMID: 12796359
   PubMed Web of Science ®Google Scholar
• Blanco G, Holli K, Heikkinen M, Kallioniemi OP, Taskinen P. Prognostic factors in recurrent breast cancer: relationships to site of recurrence, disease-free interval, female sex steroid receptors, ploidy and histological malignancy grading. Br J Cancer 1990; 62:142 - 6; http://dx.doi.org/10.1038/bjc.1990.247; PMID: 2390476
   PubMed Web of Science ®Google Scholar
• Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002; 2:563 - 72; http://dx.doi.org/10.1038/nrc865; PMID: 12154349
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646 - 74; http://dx.doi.org/10.1016/j.cell.2011.02.013; PMID: 21376230
   PubMed Web of Science ®Google Scholar
• Harbour JW, Luo RX, Dei Santi A, Postigo AA, Dean DC. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 1999; 98:859 - 69; http://dx.doi.org/10.1016/S0092-8674(00)81519-6; PMID: 10499802
   PubMed Web of Science ®Google Scholar
• Courjal F, Louason G, Speiser P, Katsaros D, Zeillinger R, Theillet C. Cyclin gene amplification and overexpression in breast and ovarian cancers: evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors. Int J Cancer 1996; 69:247 - 53; http://dx.doi.org/10.1002/(SICI)1097-0215(19960822)69:4<247::AID-IJC1>3.0.CO;2-X; PMID: 8797862
   PubMed Web of Science ®Google Scholar
• Gillett C, Smith P, Gregory W, Richards M, Millis R, Peters G, et al. Cyclin D1 and prognosis in human breast cancer. Int J Cancer 1996; 69:92 - 9; http://dx.doi.org/10.1002/(SICI)1097-0215(19960422)69:2<92::AID-IJC4>3.0.CO;2-Q; PMID: 8608989
   PubMed Web of Science ®Google Scholar
• McIntosh GG, Anderson JJ, Milton I, Steward M, Parr AH, Thomas MD, et al. Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene 1995; 11:885 - 91; PMID: 7675447
   PubMed Web of Science ®Google Scholar
• Casimiro MC, Pestell RG. Cyclin d1 induces chromosomal instability. Oncotarget 2012; 3:224 - 5; PMID: 22538871
   PubMed Web of Science ®Google Scholar
• Leontieva OV, Lenzo F, Demidenko ZN, Blagosklonny MV. Hyper-mitogenic drive coexists with mitotic incompetence in senescent cells. Cell Cycle 2012; 11:4642 - 9; http://dx.doi.org/10.4161/cc.22937; PMID: 23187803
   PubMed Web of Science ®Google Scholar
• Wang C, Li Z, Lu Y, Du R, Katiyar S, Yang J, et al. Cyclin D1 repression of nuclear respiratory factor 1 integrates nuclear DNA synthesis and mitochondrial function. Proc Natl Acad Sci USA 2006; 103:11567 - 72; http://dx.doi.org/10.1073/pnas.0603363103; PMID: 16864783
   PubMed Web of Science ®Google Scholar
• Ezhevsky SA, Ho A, Becker-Hapak M, Davis PK, Dowdy SF. Differential regulation of retinoblastoma tumor suppressor protein by G(1) cyclin-dependent kinase complexes in vivo. Mol Cell Biol 2001; 21:4773 - 84; http://dx.doi.org/10.1128/MCB.21.14.4773-4784.2001; PMID: 11416152
   PubMed Web of Science ®Google Scholar
• Ezhevsky SA, Nagahara H, Vocero-Akbani AM, Gius DR, Wei MC, Dowdy SF. Hypo-phosphorylation of the retinoblastoma protein (pRb) by cyclin D:Cdk4/6 complexes results in active pRb. Proc Natl Acad Sci USA 1997; 94:10699 - 704; http://dx.doi.org/10.1073/pnas.94.20.10699; PMID: 9380698
   PubMed Web of Science ®Google Scholar
• Lundberg AS, Weinberg RA. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol 1998; 18:753 - 61; PMID: 9447971
   PubMed Web of Science ®Google Scholar
• Reddy HK, Mettus RV, Rane SG, Graña X, Litvin J, Reddy EP. Cyclin-dependent kinase 4 expression is essential for neu-induced breast tumorigenesis. Cancer Res 2005; 65:10174 - 8; http://dx.doi.org/10.1158/0008-5472.CAN-05-2639; PMID: 16288002
   PubMed Web of Science ®Google Scholar
• Lapointe J, Lachance Y, Labrie Y, Labrie C. A p18 mutant defective in CDK6 binding in human breast cancer cells. Cancer Res 1996; 56:4586 - 9; PMID: 8840966
   PubMed Web of Science ®Google Scholar
• Dean JL, McClendon AK, Hickey TE, Butler LM, Tilley WD, Witkiewicz AK, et al. Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. Cell Cycle 2012; 11:2756 - 61; http://dx.doi.org/10.4161/cc.21195; PMID: 22767154
   PubMed Web of Science ®Google Scholar
• Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 2009; 11:R77; http://dx.doi.org/10.1186/bcr2419; PMID: 19874578
   PubMed Web of Science ®Google Scholar
• Fry DW, Bedford DC, Harvey PH, Fritsch A, Keller PR, Wu Z, et al. Cell cycle and biochemical effects of PD 0183812. A potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6. J Biol Chem 2001; 276:16617 - 23; http://dx.doi.org/10.1074/jbc.M008867200; PMID: 11278443
   PubMed Web of Science ®Google Scholar
• Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 2004; 3:1427 - 38; PMID: 15542782
   PubMed Web of Science ®Google Scholar
• McClendon AK, Dean JL, Rivadeneira DB, Yu JE, Reed CA, Gao E, et al. CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy. Cell Cycle 2012; 11:2747 - 55; http://dx.doi.org/10.4161/cc.21127; PMID: 22751436
   PubMed Web of Science ®Google Scholar
• Talmadge JE, Fidler IJ. AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res 2010; 70:5649 - 69; http://dx.doi.org/10.1158/0008-5472.CAN-10-1040; PMID: 20610625
   PubMed Web of Science ®Google Scholar
• Cheng CW, Wu PE, Yu JC, Huang CS, Yue CT, Wu CW, et al. Mechanisms of inactivation of E-cadherin in breast carcinoma: modification of the two-hit hypothesis of tumor suppressor gene. Oncogene 2001; 20:3814 - 23; http://dx.doi.org/10.1038/sj.onc.1204505; PMID: 11439345
   PubMed Web of Science ®Google Scholar
• Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004; 117:927 - 39; http://dx.doi.org/10.1016/j.cell.2004.06.006; PMID: 15210113
   PubMed Web of Science ®Google Scholar
• Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100:3983 - 8; http://dx.doi.org/10.1073/pnas.0530291100; PMID: 12629218
   PubMed Web of Science ®Google Scholar
• Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 2009; 69:1302 - 13; http://dx.doi.org/10.1158/0008-5472.CAN-08-2741; PMID: 19190339
   PubMed Web of Science ®Google Scholar
• Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007; 1:555 - 67; http://dx.doi.org/10.1016/j.stem.2007.08.014; PMID: 18371393
   PubMed Web of Science ®Google Scholar
• Lai VK, Ashraf M, Jiang S, Haider K. MicroRNA-143 is a critical regulator of cell cycle activity in stem cells with co-overexpression of Akt and angiopoietin-1 via transcriptional regulation of Erk5/cyclin D1 signaling. Cell Cycle 2012; 11:767 - 77; http://dx.doi.org/10.4161/cc.11.4.19211; PMID: 22374674
   PubMed Web of Science ®Google Scholar
• Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008; 100:672 - 9; http://dx.doi.org/10.1093/jnci/djn123; PMID: 18445819
   PubMed Web of Science ®Google Scholar
• Phillips TM, McBride WH, Pajonk F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 2006; 98:1777 - 85; http://dx.doi.org/10.1093/jnci/djj495; PMID: 17179479
   PubMed Web of Science ®Google Scholar
• Lehn S, Tobin NP, Berglund P, Nilsson K, Sims AH, Jirström K, et al. Down-regulation of the oncogene cyclin D1 increases migratory capacity in breast cancer and is linked to unfavorable prognostic features. Am J Pathol 2010; 177:2886 - 97; http://dx.doi.org/10.2353/ajpath.2010.100303; PMID: 20971731
   PubMed Web of Science ®Google Scholar
• Schwartz GK, LoRusso PM, Dickson MA, Randolph SS, Shaik MN, Wilner KD, et al. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). Br J Cancer 2011; 104:1862 - 8; http://dx.doi.org/10.1038/bjc.2011.177; PMID: 21610706
   PubMed Web of Science ®Google Scholar
• Fornier MN, Rathkopf D, Shah M, Patil S, O’Reilly E, Tse AN, et al. Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors. Clin Cancer Res 2007; 13:5841 - 6; http://dx.doi.org/10.1158/1078-0432.CCR-07-1218; PMID: 17908977
   PubMed Web of Science ®Google Scholar
• Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007; 131:1109 - 23; http://dx.doi.org/10.1016/j.cell.2007.10.054; PMID: 18083101
   PubMed Web of Science ®Google Scholar
• Lapidus RG, Ferguson AT, Ottaviano YL, Parl FF, Smith HS, Weitzman SA, et al. Methylation of estrogen and progesterone receptor gene 5′ CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. Clin Cancer Res 1996; 2:805 - 10; PMID: 9816234
   PubMed Web of Science ®Google Scholar
• Du J, Zhou N, Liu H, Jiang F, Wang Y, Hu C, et al. Arsenic induces functional re-expression of estrogen receptor α by demethylation of DNA in estrogen receptor-negative human breast cancer. PLoS One 2012; 7:e35957; http://dx.doi.org/10.1371/journal.pone.0035957; PMID: 22558281
   PubMed Web of Science ®Google Scholar
• Keen JC, Yan L, Mack KM, Pettit C, Smith D, Sharma D, et al. A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2′-deoxycytidine. Breast Cancer Res Treat 2003; 81:177 - 86; http://dx.doi.org/10.1023/A:1026146524737; PMID: 14620913
   PubMed Web of Science ®Google Scholar
• Yang X, Phillips DL, Ferguson AT, Nelson WG, Herman JG, Davidson NE. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res 2001; 61:7025 - 9; PMID: 11585728
   PubMed Web of Science ®Google Scholar
• Li Y, Yuan YY, Meeran SM, Tollefsbol TO. Synergistic epigenetic reactivation of estrogen receptor-α (ERα) by combined green tea polyphenol and histone deacetylase inhibitor in ERα-negative breast cancer cells. Mol Cancer 2010; 9:274; http://dx.doi.org/10.1186/1476-4598-9-274; PMID: 20946668
   PubMed Web of Science ®Google Scholar
• Jirawatnotai S, Hu Y, Livingston DM, Sicinski P. Proteomic identification of a direct role for cyclin d1 in DNA damage repair. Cancer Res 2012; 72:4289 - 93; http://dx.doi.org/10.1158/0008-5472.CAN-11-3549; PMID: 22915759
   PubMed Web of Science ®Google Scholar
• Wang C, Lisanti MP, Liao DJ. Reviewing once more the c-myc and Ras collaboration: converging at the cyclin D1-CDK4 complex and challenging basic concepts of cancer biology. Cell Cycle 2011; 10:57 - 67; http://dx.doi.org/10.4161/cc.10.1.14449; PMID: 21200143
   PubMed Web of Science ®Google Scholar
• Carlson B, Lahusen T, Singh S, Loaiza-Perez A, Worland PJ, Pestell R, et al. Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res 1999; 59:4634 - 41; PMID: 10493518
   PubMed Web of Science ®Google Scholar